-
Je něco špatně v tomto záznamu ?
Molecularly targeted protease-activated probes for visualization of glioblastoma: a comparison with 5-ALA
D. Konečná, P. Výmola, N. Ternerová, B. Výmolová, E. Garcia-Borja, R. Mateu, F. Šroubek, J. Pankrác, JC. Widen, M. Bogyo, D. Netuka, P. Bušek, A. Šedo
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, srovnávací studie
PubMed
38552239
DOI
10.3171/2024.1.jns231137
Knihovny.cz E-zdroje
- MeSH
- fluorescenční barviva MeSH
- glioblastom * diagnostické zobrazování patologie MeSH
- kyselina aminolevulová * MeSH
- lidé MeSH
- molekulární sondy MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory mozku * diagnostické zobrazování patologie MeSH
- optické zobrazování metody MeSH
- proteasy metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
OBJECTIVE: The highly infiltrative growth of glioblastoma (GBM) makes distinction between the tumor and normal brain tissue challenging. Therefore, fluorescence-guided surgery is often used to improve visual identification of radiological tumor margins. The aim of this study was to evaluate the ability of recently developed molecularly targeted near-infrared (NIR) protease-activated probes to visualize GBM tissue and to compare the most promising candidate with the gold standard, 5-aminolevulinic acid (5-ALA). METHODS: Single-substrate probes 6QC-ICG and 6QC-Cy5 (cysteine cathepsin cleavable), double-substrate probes AG2-FNIR and AG2-Cy5 (cysteine cathepsin and caspase 3 cleavable), and 5-ALA were administered intravenously to mice with orthotopic tumors. Activation of the probes was also evaluated in cell cultures in vitro and in biopsy material from patients with GBM ex vivo. The tumor to normal brain tissue fluorescence ratio (TNR) was quantified in brain sections using preclinical and clinical visualization platforms, and in tissue homogenates and cell suspensions using spectrofluorimetry. Subcellular localization of the fluorophores was visualized by confocal microscopy. RESULTS: In vitro, the single-substrate probe 6QC-ICG was cleaved in glioma cells and macrophages, and the resulting fluorophore accumulated intracellularly. In experimental GBMs, both single- and double-substrate probes visualized tumor tissue, while in healthy brain tissue the signal was minimal. TNR was highest for 6QC-ICG and AG2-FNIR, but the signal intensity was higher for 6QC-ICG. Using xenograft and syngeneic mouse models, as well as human GBM biopsy material ex vivo, the authors confirmed the ability of 6QC-ICG to specifically visualize the glioma tissue using preclinical and clinical visualization platforms. Finally, a comparison with 5-ALA in animals coadministered with both compounds revealed a higher TNR for 6QC-ICG in experimental GBMs. CONCLUSIONS: The cysteine cathepsin-cleavable probe 6QC-ICG is activated by glioma cells and tumor-associated macrophages, leading to a high contrast between tumor and nontumorous brain tissue that is superior to that of the current standard, 5-ALA. In addition to a well-defined mechanism of action, protease-activated probes that use NIR fluorophores (e.g., indocyanine green) have the advantage of low absorption and scattering of the NIR light and lower tissue autofluorescence. These results suggest that 6QC-ICG has the potential to become the targeted agent in intraoperative detection of GBM tissue using fluorescence imaging.
Department of Pathology Stanford University School of Medicine Stanford California
Institute of Information Theory and Automation Czech Academy of Sciences Prague
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019200
- 003
- CZ-PrNML
- 005
- 20241024111436.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3171/2024.1.JNS231137 $2 doi
- 035 __
- $a (PubMed)38552239
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Konečná, Dora $u 1Department of Neurosurgery and Neurooncology, First Faculty of Medicine and Military University Hospital, Prague $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 245 10
- $a Molecularly targeted protease-activated probes for visualization of glioblastoma: a comparison with 5-ALA / $c D. Konečná, P. Výmola, N. Ternerová, B. Výmolová, E. Garcia-Borja, R. Mateu, F. Šroubek, J. Pankrác, JC. Widen, M. Bogyo, D. Netuka, P. Bušek, A. Šedo
- 520 9_
- $a OBJECTIVE: The highly infiltrative growth of glioblastoma (GBM) makes distinction between the tumor and normal brain tissue challenging. Therefore, fluorescence-guided surgery is often used to improve visual identification of radiological tumor margins. The aim of this study was to evaluate the ability of recently developed molecularly targeted near-infrared (NIR) protease-activated probes to visualize GBM tissue and to compare the most promising candidate with the gold standard, 5-aminolevulinic acid (5-ALA). METHODS: Single-substrate probes 6QC-ICG and 6QC-Cy5 (cysteine cathepsin cleavable), double-substrate probes AG2-FNIR and AG2-Cy5 (cysteine cathepsin and caspase 3 cleavable), and 5-ALA were administered intravenously to mice with orthotopic tumors. Activation of the probes was also evaluated in cell cultures in vitro and in biopsy material from patients with GBM ex vivo. The tumor to normal brain tissue fluorescence ratio (TNR) was quantified in brain sections using preclinical and clinical visualization platforms, and in tissue homogenates and cell suspensions using spectrofluorimetry. Subcellular localization of the fluorophores was visualized by confocal microscopy. RESULTS: In vitro, the single-substrate probe 6QC-ICG was cleaved in glioma cells and macrophages, and the resulting fluorophore accumulated intracellularly. In experimental GBMs, both single- and double-substrate probes visualized tumor tissue, while in healthy brain tissue the signal was minimal. TNR was highest for 6QC-ICG and AG2-FNIR, but the signal intensity was higher for 6QC-ICG. Using xenograft and syngeneic mouse models, as well as human GBM biopsy material ex vivo, the authors confirmed the ability of 6QC-ICG to specifically visualize the glioma tissue using preclinical and clinical visualization platforms. Finally, a comparison with 5-ALA in animals coadministered with both compounds revealed a higher TNR for 6QC-ICG in experimental GBMs. CONCLUSIONS: The cysteine cathepsin-cleavable probe 6QC-ICG is activated by glioma cells and tumor-associated macrophages, leading to a high contrast between tumor and nontumorous brain tissue that is superior to that of the current standard, 5-ALA. In addition to a well-defined mechanism of action, protease-activated probes that use NIR fluorophores (e.g., indocyanine green) have the advantage of low absorption and scattering of the NIR light and lower tissue autofluorescence. These results suggest that 6QC-ICG has the potential to become the targeted agent in intraoperative detection of GBM tissue using fluorescence imaging.
- 650 12
- $a glioblastom $x diagnostické zobrazování $x patologie $7 D005909
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a nádory mozku $x diagnostické zobrazování $x patologie $7 D001932
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kyselina aminolevulová $7 D000622
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a fluorescenční barviva $7 D005456
- 650 _2
- $a proteasy $x metabolismus $7 D010447
- 650 _2
- $a molekulární sondy $7 D015335
- 650 _2
- $a optické zobrazování $x metody $7 D061848
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Výmola, Petr $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 700 1_
- $a Ternerová, Nikola $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 700 1_
- $a Výmolová, Barbora $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 700 1_
- $a Garcia-Borja, Elena $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 700 1_
- $a Mateu, Rosana $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 700 1_
- $a Šroubek, Filip $u 3Institute of Information Theory and Automation, Czech Academy of Sciences, Prague
- 700 1_
- $a Pankrác, Jan $u 4Center of Advanced Preclinical Imaging, First Faculty of Medicine, Charles University, Prague, Czech Republic; and
- 700 1_
- $a Widen, John C $u 5Department of Pathology, Stanford University School of Medicine, Stanford, California
- 700 1_
- $a Bogyo, Matthew $u 5Department of Pathology, Stanford University School of Medicine, Stanford, California
- 700 1_
- $a Netuka, David $u 1Department of Neurosurgery and Neurooncology, First Faculty of Medicine and Military University Hospital, Prague
- 700 1_
- $a Bušek, Petr $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 700 1_
- $a Šedo, Aleksi $u 2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague
- 773 0_
- $w MED00002843 $t Journal of neurosurgery $x 1933-0693 $g Roč. 141, č. 3 (2024), s. 602-613
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38552239 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111429 $b ABA008
- 999 __
- $a ok $b bmc $g 2201816 $s 1231173
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 141 $c 3 $d 602-613 $e 20240329 $i 1933-0693 $m Journal of neurosurgery $n J Neurosurg $x MED00002843
- LZP __
- $a Pubmed-20241015